San Francisco startup Composition Therapeutics is usually working on an oral, once-every day GLP-1 drug known as GSBR-1290—the drug surpassed Wall Street’s expectations in June whenever a mid-phase research confirmed typical weight loss of close to 6% and it plans to start An additional mid-phase trial toward the tip of this year—that founder